Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
ArriVent BioPharma, Inc.
organization3 mentionslast seen Oct 26, 2026
Clinical-stage biopharmaceutical company developing firmonertinib for cancer treatment.
Relationships 9
- ArriVent BioPharma, Inc.employsBing Yao99% confidence2 sources
- ArriVent BioPharma, Inc.developsfirmonertinib99% confidence2 sources
- ArriVent BioPharma, Inc.employsWinston Kung99% confidence2 sources
- ArriVent BioPharma, Inc.employsStuart Lutzker97% confidence1 source
- ArriVent BioPharma, Inc.developsARR-00295% confidence1 source
- ArriVent BioPharma, Inc.developsARR-21793% confidence1 source
- Lepu Biopharma Co., Ltd.partners withArriVent BioPharma, Inc.90% confidence1 source
- ArriVent BioPharma, Inc.partners withAllist88% confidence1 source
- ArriVent BioPharma, Inc.developsALPACCA88% confidence1 source
Relationship
ArriVent BioPharma, Inc.developsfirmonertinib
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 13, 2026ArriVent BioPharma, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
maximize the potential of its lead development candidate, firmonertinib
- filingSEC EDGAROct 6, 2026ArriVent BioPharma, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
ArriVent BioPharma, Inc. issued a press release announcing an update from the Phase 3 FURVENT trial of firmonertinib